Novartis blood-pressure drug Diovan has wider use, tests show
ZURICH (MarketWatch) -- Swiss drugmaker Novartis AG (NVS) Friday said its best-selling blood pressure medicine Diovan also helps to lower levels of a marker of inflammation, which is considered to be a risk factor for heart attacks and stroke.
Basel, Switzerland-based Novartis said that in a study involving 1,668 patients, Diovan was found to lower the level of an inflammatory marker called high sensitivity C-reactive protein, or hsCRP, independently of the drug's established ability to lower blood pressure.
· Read The Full Heart Attacks Article From MarketWatch -->
·
Read All Heart Attacks News Stories -->